| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 145, 1296-1300, Copyright © 1994 by American Society for Investigative Pathology
REGULAR ARTICLES |
M Ladanyi, G Cavalchire, SW Morris, J Downing and DA Filippa
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Hodgkin's disease (HD) and Ki-1 positive anaplastic large cell lymphoma (Ki-1 ALCL) appear pathologically and immunohistochemically related, and a common histogenesis has been postulated in at least some cases. The breakpoints of the t(2;5) (p23;q35) [corrected] translocation, which is reported in about 40% of Ki-1 ALCL, have recently been cloned. They involve a novel tyrosine kinase gene, ALK, at 2p23 and the nucleophosmin gene, NPM, at 5q35. Reverse transcriptase polymerase chain reaction (RT-PCR) using NPM and ALK primers consistently detects a fusion product in Ki-1 ALCL cases with the translocation. To determine if this tumor-specific genetic alteration also occurs in HD, we performed NPM-ALK RT-PCR on RNA samples extracted from 40 lymph node biopsies of HD (25 nodular sclerosis, 11 mixed cellularity, 2 lymphocyte depleted, 2 lymphocyte predominant). Using control samples, the sensitivity of the NPM-ALK RT-PCR assay was shown to be at least 1:10(4). Amplifiable template was confirmed in all samples by RT-PCR using beta-actin primers. None of the 40 cases showed the expected 177- bp RT-PCR product indicative of the translocation. We conclude that the most common primary genetic alteration in Ki-1 ALCL, the t(2;5), is absent or very infrequent in typical cases of HD. These results further support the concept that HD and Ki-1 ALCL are pathogenetically distinct entities.
This article has been cited by other articles:
 |
|
 |
|
  J. A. Schumacher, D. K. Crockett, K. S.J. Elenitoba-Johnson, and M. S. Lim Evaluation of Enrichment Techniques for Mass Spectrometry: Identification of Tyrosine Phosphoproteins in Cancer Cells J. Mol. Diagn., April 1, 2007; 9(2): 169 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Kutok and J. C. Aster Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma J. Clin. Oncol., September 1, 2002; 20(17): 3691 - 3702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R L Ten Berge, F G M Snijdewint, S von Mensdorff-Pouilly, R J J Poort-Keesom, J J Oudejans, J W R Meijer, R Willemze, J Hilgers, and C J L M Meijer MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form J. Clin. Pathol., December 1, 2001; 54(12): 933 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features Blood, December 1, 2000; 96(12): 3681 - 3695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Arber Molecular Diagnostic Approach to Non-Hodgkin's Lymphoma J. Mol. Diagn., November 1, 2000; 2(4): 178 - 190. [Full Text]
|
|
|
|
|
|
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype Blood, November 1, 2000; 96(9): 2993 - 3000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Macintyre, D. Willerford, and S. W. Morris Non-Hodgkin's Lymphoma: Molecular Features of B Cell Lymphoma Hematology, January 1, 2000; 2000(1): 180 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Melnick and J. D. Licht Deconstructing a Disease: RAR{alpha}, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia Blood, May 15, 1999; 93(10): 3167 - 3215. [Full Text] [PDF]
|
|
|
|
|
|
K. Pulford, L. Lamant, S. W. Morris, L. H. Butler, K. M. Wood, D. Stroud, G. Delsol, and D. Y. Mason Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1 Blood, February 15, 1997; 89(4): 1394 - 1404. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
